Balyasny Asset Management Increases Stake in Beyond Air Inc. Despite Financial Challenges

Balyasny Asset Management has acquired an additional 447,825.2 shares of Beyond Air Inc. at $3.446 per share, increasing its total holdings to 614,545.65 shares. The firm's investment in the medical devices sector reflects its focus on growth opportunities and potential for long-term growth despite the company's current financial challenges.

Balyasny Asset Management has increased its ownership in Beyond Air Inc. (NASDAQ:XAIR) by acquiring an additional 447,825.2 shares at $3.446 per share. This purchase brings Balyasny's total holdings to 614,545.65 shares. The investment underscores the asset management firm's commitment to the medical devices sector, highlighting potential growth opportunities despite Beyond Air's current financial challenges.

The acquisition comes as Beyond Air reported a 157% year-over-year increase in GAAP revenue to $1.8 million for the first quarter of fiscal 2026, despite missing analyst estimates by 27.5% [2]. Earnings per share (GAAP) improved to $(1.53), which was $0.96 better than the prior year's GAAP loss of $(5.32). The company's expansion into international markets and cost reductions in research and development and selling, general, and administrative expenses contributed to the quarter's performance.

Balyasny's investment aligns with Beyond Air's strategic focus on regulatory approvals, clinical trial progress, and distribution agreements. The company's LungFit product family, which generates nitric oxide from ambient air, is poised to disrupt the traditional cylinder-based systems used in hospitals. The recent regulatory approvals in Europe, the Middle East, and Asia, along with the company's ongoing pipeline development, position Beyond Air for significant growth.

However, financial stability remains a concern. The company reported a net loss for the quarter and a cash position of $6.5 million at the end of the period. The company's runway is highly dependent on meeting sales targets and maintaining spending discipline. Balyasny's investment reflects a belief in the long-term potential of Beyond Air's innovative nitric oxide therapies and the company's ability to navigate its current financial challenges.

References:
[1] https://www.secform4.com/13dg-holding-history/1218710/08862L202.html
[2] https://www.nasdaq.com/articles/beyond-air-sales-jump-158-percent